Research paperRepurposing of commercially available anti-coccidials identifies diclazuril and Decoquinate (cas 18507-89-6) as potential therapeutic candidates against Besnoitia besnoiti infection
-
Add time:09/05/2019 Source:sciencedirect.com
Repurposing of currently marketed compounds with proven efficacy against apicomplexan parasites was used as an approach to define novel candidate therapeutics for bovine besnoitiosis. Besnoitia besnoiti tachyzoites grown in MARC-145 cells were exposed to different concentrations of toltrazuril, diclazuril, imidocarb, Decoquinate (cas 18507-89-6), sulfadiazine and trimethoprim alone or in combination with sulfadiazine. Drugs were added either just prior to infection of MARC-145 cells (0 h post infection, hpi) or at 6 hpi. A primary evaluation of drug effects was done by direct immunofluorescence staining and counting. Potential effects on the host cells were assessed using a XTT kit for cell proliferation. Compounds displaying promising efficacy were selected for IC50 and IC99 determination by qPCR. In addition, the impact of drugs on the tachyzoite ultrastructure was assessed by TEM and long-term treatment assays were performed. Cytotoxicity assays confirmed that none of the compounds affected the host cells. Decoquinate and diclazuril displayed invasion inhibition rates of 90 and 83% at 0 h pi and 73 and 72% at 6 h pi, respectively. The remaining drugs showed lower efficacy and were not further studied. Decoquinate and diclazuril exhibited IC99 values of 100 nM and 29.9 μM, respectively. TEM showed that decoquinate primarily affected the parasite mitochondrium, whilst diclazuril interfered in cytokinesis of daughter zoites. The present study demonstrates the efficacy of diclazuril and decoquinate against B. besnoiti in vitro and further assessments of safety and efficacy of both drugs should be performed in the target species.
We also recommend Trading Suppliers and Manufacturers of Decoquinate (cas 18507-89-6). Pls Click Website Link as below: cas 18507-89-6 suppliers
Prev:Short CommunicationExploring the association between E-cigarette retailer proximity and density to schools and youth E-cigarette use
Next:Efficacy of Decoquinate (cas 18507-89-6) against Sarcocystis neurona in cell cultures) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Decoquinate (cas 18507-89-6) induces tissue cyst formation by the RH strain of Toxoplasma gondii09/27/2019
- Efficacy of Decoquinate (cas 18507-89-6) against Neospora caninum tachyzoites in cell cultures09/26/2019
- Short communicationActivity of Decoquinate (cas 18507-89-6) against Cryptosporidium parvum in cell cultures and neonatal mice09/25/2019
- Tracing the emergence of drug-resistance in coccidia (Eimeria spp.) of commercial broiler flocks medicated with Decoquinate (cas 18507-89-6) for the first time in the United Kingdom09/24/2019
- Efficacy of Decoquinate (cas 18507-89-6) against drug sensitive laboratory strains of Eimeria tenella and field isolates of Eimeria spp. in broiler chickens in China09/10/2019
- Research ArticleNanoparticle formulations of Decoquinate (cas 18507-89-6) increase antimalarial efficacy against liver stage Plasmodium infections in mice09/09/2019
- Straightforward conversion of Decoquinate (cas 18507-89-6) into inexpensive tractable new derivatives with significant antimalarial activities09/08/2019
- Original articleDecoquinate (cas 18507-89-6) derivatives: A new class of potent antischistosomal agents against Schistosoma japonicum09/07/2019
- Efficacy of Decoquinate (cas 18507-89-6) against Sarcocystis neurona in cell cultures09/06/2019